微泰医疗-B(02235)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02235 微泰医疗-B

已收盘 09-07 16:08:15

6.700

-0.100

-1.47%

最高7.055	最低6.585	成交量20.22万
今开7.055	昨收6.800	日振幅6.91%
总市值27.81亿	流通市值10.99亿	总股本4.15亿
成交额135.96万	换手率0.12%	流通股本1.64亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02235","market":"HK","secType":"STK","nameCN":"微泰医疗-B","latestPrice":6.7,"timestamp":1788768495109,"preClose":6.8,"halted":0,"volume":202200,"delay":0,"changeRate":-0.014705882352941124,"floatShares":164000000,"shares":415000000,"eps":0.097161,"marketStatus":"已收盘","change":-0.1,"latestTime":"09-07 16:08:15","open":7.055,"high":7.055,"low":6.585,"amount":1359599,"amplitude":0.069118,"askPrice":6.85,"askSize":20200,"bidPrice":6.7,"bidSize":100,"shortable":0,"etf":0,"ttmEps":0.229,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1788831000000},"marketStatusCode":5,"adr":0,"listingDate":1634572800000,"exchange":"SEHK","adjPreClose":6.8,"openAndCloseTimeList":[[1788744600000,1788753600000],[1788757200000,1788768000000]],"volumeRatio":1.285278,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02235","defaultTab":"news","newsList":[{"id":"2665319250","title":"微泰医疗-B：新一代分体式持续葡萄糖监测系统获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2665319250","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665319250?lang=zh_cn&edition=full","pubTime":"2026-09-07 19:30","pubTimestamp":1788780600,"startTime":"0","endTime":"0","summary":"9月7日，微泰医疗-B（02235）发布公告，近日公司新一代分体式持续葡萄糖监测系统AiDEXG9获得国家药品监督管理局的上市批准。该产品相较于第一代分体式产品实现了技术架构的创新变革，并在体积、轻便度与佩戴舒适度上全面升级，为糖尿病患者提供更轻盈、更自信的血糖管理体验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609073866847884.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609073866847884.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02235","BK1100","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199865302","title":"微泰医疗-B回购26,200股股份，总额约17.46万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1199865302","media":"公告速递","labels":["shareholding","SGX"],"top":1,"itemType":null,"share":"https://www.laohunote.com/m/news/1199865302?lang=zh_cn&edition=full","pubTime":"2026-09-07 19:15","pubTimestamp":1788779755,"startTime":"0","endTime":"0","summary":"微泰医疗器械（杭州）股份有限公司于2026年9月7日发布公告称，公司于当日回购26,200股普通H股，约占回购前已发行股份总数的0.0161%。本次回购股份的最高价为每股6.70港元，最低价为每股6.60港元，合计付出价款约17.46万港元。回购完成后，公司已发行股份数降至163,154,342股，库存股份增加至6,021,500股，合计股份总数保持为169,175,842股。公告显示，该次回购系根据2026年6月10日通过的股份购回授权进行，授予公司可回购最多16,416,184股的权限。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"微泰医疗-B回购26,200股股份，总额约17.46万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02235"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665131981","title":"微泰医疗-B(02235)9月7日斥资17.46万港元回购2.62万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2665131981","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665131981?lang=zh_cn&edition=full","pubTime":"2026-09-07 19:11","pubTimestamp":1788779509,"startTime":"0","endTime":"0","summary":"智通财经APP讯，微泰医疗-B(02235)发布公告，于2026年9月7日斥资17.46万港元回购2.62万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1492953.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02235","BK1100"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665319893","title":"微泰医疗-B(02235.HK)：持续葡萄糖监测系统AiDEX G9获国家药品监督管理局注册批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2665319893","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665319893?lang=zh_cn&edition=full","pubTime":"2026-09-07 19:11","pubTimestamp":1788779501,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1100","02235"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174921206","title":"微泰医疗-B（02235）新一代CGM系统AiDEX G9获国家药监局上市批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1174921206","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1174921206?lang=zh_cn&edition=full","pubTime":"2026-09-07 19:11","pubTimestamp":1788779487,"startTime":"0","endTime":"0","summary":"2026年9月7日，微泰医疗器械（杭州）股份有限公司公告称，其新一代分体式持续葡萄糖监测系统AiDEX G9已获得国家药品监督管理局注册批准。据公告，AiDEX G9相较公司第一代分体式产品在技术架构、体积、轻便度及佩戴舒适度等方面全面升级，旨在为糖尿病患者提供更轻盈、自在的血糖管理体验。微泰医疗-B同时提醒投资者，相关产品的生产、销售及收益仍受市场等多重因素影响，投资者在买卖公司股份时需审慎行事。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02235"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1140436721","title":"微泰医疗-B（杭州）旗下Aidex G9获中国国家药品监督管理局上市批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1140436721","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1140436721?lang=zh_cn&edition=full","pubTime":"2026-09-07 19:08","pubTimestamp":1788779294,"startTime":"0","endTime":"0","summary":"微泰医疗-B（杭州）宣布，其Aidex G9产品已正式获得中国国家药品监督管理局（NMPA）的上市批准。这一里程碑式的进展，标志着该公司在医疗器械领域的又一重要突破。Aidex G9的获批，不仅彰显了微泰医疗在技术创新与质量管控上的深厚积累，也为其进一步拓展国内市场份额奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1100","02235"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142920246","title":"微泰医疗-B公布2026年8月股份变动月报 股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1142920246","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1142920246?lang=zh_cn&edition=full","pubTime":"2026-09-01 17:06","pubTimestamp":1788253577,"startTime":"0","endTime":"0","summary":"微泰医疗器械（杭州）股份有限公司于2026年9月1日发布2026年8月股份变动月报，报告期为2026年8月1日至2026年8月31日。公告显示，截至本月底，公司各类股份数目与上月底保持一致，整体股本规模未发生变化。公告进一步指出，公司在2026年8月内未发生新增发行、购回或注销、库存股份变化等事宜，也无股份期权、供股计划或可换股票据等方面的变动。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02235"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185287203","title":"微泰医疗-B（02235）2026年上半年营收4.14亿元 净利润4,027万元实现扭亏","url":"https://stock-news.laohu8.com/highlight/detail?id=1185287203","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1185287203?lang=zh_cn&edition=full","pubTime":"2026-08-21 21:15","pubTimestamp":1787318149,"startTime":"0","endTime":"0","summary":"香港联合交易所上市公司微泰医疗-B8月21日披露2026年中期业绩。报告期内，公司实现营业收入4.14亿元，同比增加68.4%；毛利2.39亿元，同比增长88.1%；毛利率由上年同期的51.7%提升至57.7%。\\n\\n公司期内实现净利润40.27百万元，较2025年同期净亏损2.29百万元大幅改善，实现扭亏为盈。销售费用1.18亿元，同比增长27.1%，费用率由37.7%降至28.5%。管理费用3,059.1万元，同比增长68.1%；研发费用4,196.6万元，同比增长28.9%。短期借款7,419.29万元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02235"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139152093","title":"微泰医疗-B（02235）签订7.5百万元原材料采购框架协议 交易构成少额持续关连交易","url":"https://stock-news.laohu8.com/highlight/detail?id=1139152093","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1139152093?lang=zh_cn&edition=full","pubTime":"2026-08-21 21:15","pubTimestamp":1787318146,"startTime":"0","endTime":"0","summary":"8月21日，微泰医疗-B公告称，公司已于2026年8月21日与杭州数康智造科技有限公司签署《原材料采购框架协议》，约定自2026年8月21日至2026年12月31日期间，双方可按各自业务需求相互采购、供应糖尿病监测、治疗及管理所需的医疗器材原材料。因在杭州数康持有约95.65%股权，郑攀博士被视为在本次交易中具有重大利益，并已于董事会相关决议中回避投票。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02235"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661929362","title":"微泰医疗-B(02235)发布中期业绩 归母净利润4027.32万元 同比扭亏为盈","url":"https://stock-news.laohu8.com/highlight/detail?id=2661929362","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661929362?lang=zh_cn&edition=full","pubTime":"2026-08-21 21:13","pubTimestamp":1787317993,"startTime":"0","endTime":"0","summary":"智通财经APP讯，微泰医疗-B(02235)发布2026年中期业绩，营业收入4.14亿元，同比增长68.4%;毛利2.39亿元，同比增长88.1%;母公司拥有人应占利润4027.32万元，同比扭亏为盈;每股盈利0.1元。公告称，收入的显著增长主要归因于持续葡萄糖监测系统国内及国际销量高速增长，胰岛素泵系统国际市场销量显著增长。净利润实现扭亏为盈，主要由于营业收入大幅攀升、毛利规模显著扩张，叠加费用率持续优化。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1483661.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02235"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194594344","title":"微泰医疗-B（02235）将于8月21日召开董事会审议2026年中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1194594344","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1194594344?lang=zh_cn&edition=full","pubTime":"2026-08-07 16:35","pubTimestamp":1786091748,"startTime":"0","endTime":"0","summary":"微泰医疗器械（杭州）股份有限公司（02235）8月7日发布公告称，公司董事会拟于2026年8月21日（星期五）召开会议，审议及批准公司及其附属公司截至2026年6月30日止六个月的未经过审计的中期业绩，并考虑建议派发中期股息（如有）。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02235"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120956240","title":"微泰医疗-B7月股份变动月报表：总股本保持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1120956240","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1120956240?lang=zh_cn&edition=full","pubTime":"2026-08-05 17:57","pubTimestamp":1785923834,"startTime":"0","endTime":"0","summary":"微泰医疗器械（杭州）股份有限公司于2026年8月5日发布了截至2026年7月31日的股份变动月报表。报告显示，公司在报告期内总股数维持在169,175,842股，未发生变化。其中，H股法定/注册股份为169,175,842股，内资股212,162,222股，非上市外资股39,739,936股，各类法定/注册股本数量均保持不变。该变动主要缘于6月10日公司按程序购回230,400股H股，并将其作为库藏股份持有，尚未进行注销操作。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02235"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112213886","title":"微泰医疗-B（02235）发布正面盈利预警：上半年收入预增至约4亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1112213886","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1112213886?lang=zh_cn&edition=full","pubTime":"2026-07-30 17:16","pubTimestamp":1785402998,"startTime":"0","endTime":"0","summary":"微泰医疗器械（杭州）股份有限公司7月30日在港交所公告，预计截至2026年6月30日止六个月的主要财务数据较去年同期显著改善。\\n\\n根据初步未经审计综合管理账目，公司预计： \\n1. 报告期间收入不低于人民币4亿元，较2025年同期的2.46亿元同比增长不低于约63%。\\n2. 归属于母公司所有者的净利润不低于人民币36百万元，扭转2025年同期净亏损人民币-2百万元的局面，实现由亏转盈。公司提醒投资者在买卖公司股份时保持审慎。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02235"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655822129","title":"微泰医疗-B(02235)发盈喜 预计中期归母净利润不低于3600万元 同比扭亏为盈","url":"https://stock-news.laohu8.com/highlight/detail?id=2655822129","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655822129?lang=zh_cn&edition=full","pubTime":"2026-07-30 17:06","pubTimestamp":1785402367,"startTime":"0","endTime":"0","summary":"智通财经APP讯，微泰医疗-B 发布公告，预计本集团截至2026年6月30日止六个月的收入将不低于人民币4亿元，对比截至2025年6 月30日止六个月的人民币2.46亿元，同比增长不低于约63%。预计本集团报告期间实现归属于母公司所有者的净利润将不低于人民币3600万元，对比2025年6月30日止六个月的人民币-200万元，实现扭亏为盈。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1474098.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"微泰医疗-B(02235)发盈喜 预计中期归母净利润不低于3600万元 同比扭亏为盈","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02235"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119241685","title":"微泰医疗-B预计2026年上半年收入至少达4亿元人民币，同比增长至少63%","url":"https://stock-news.laohu8.com/highlight/detail?id=1119241685","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1119241685?lang=zh_cn&edition=full","pubTime":"2026-07-30 17:05","pubTimestamp":1785402308,"startTime":"0","endTime":"0","summary":"微泰医疗-B（MICROTECH MED-B）发布公告，预计截至2026年6月30日的六个月期间，收入将不低于人民币4亿元。与去年同期相比，这一数字至少增长了63%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02235","BK1100"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124830131","title":"微泰医疗-B7月21日回购1900股股份，耗资约1.35万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1124830131","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1124830131?lang=zh_cn&edition=full","pubTime":"2026-07-21 18:30","pubTimestamp":1784629854,"startTime":"0","endTime":"0","summary":"微泰医疗器械（杭州）股份有限公司于2026年7月21日发布翌日披露报表，公告当日公司于香港联交所回购普通股1900股，占回购前已发行股本约0.0012%。回购价格每股介于7.09港元至7.10港元，合计耗资13,482港元，折合约1.35万港元。该次回购后，公司已发行股本下降至163,180,542股，库藏股增至5,995,300股，总发行股本仍为169,175,842股。基于上市规则要求，在本次回购后30天内，公司不得在未获交易所批准的情况下发行新股或出售、转让任何库藏股。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"微泰医疗-B7月21日回购1900股股份，耗资约1.35万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02235"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124048816","title":"微泰医疗-B回购1.07万股股份，耗资约7.49万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1124048816","media":"公告速递","labels":["shareholding","buyback","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1124048816?lang=zh_cn&edition=full","pubTime":"2026-07-20 19:12","pubTimestamp":1784545939,"startTime":"0","endTime":"0","summary":"2026年7月20日，微泰医疗器械（杭州）股份有限公司发布公告称，公司于当日通过香港联交所场内回购1.07万股H股，约占该公司回购前已发行股本的0.0066%。回购价格区间为每股6.98港元至7.00港元，合计耗资约7.49万港元。回购完成后，公司已发行股本由163,193,142股减少至163,182,442股，同时库藏股增至5,993,400股，总已发行股份数维持169,175,842股不变。该授权下公司可回购股份总数为16,416,184股，截至目前累计已回购562,600股，占授权通过当日已发行股本总数的0.3436%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"微泰医疗-B回购1.07万股股份，耗资约7.49万港元","news_tag":"shareholding,buyback,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02235"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652502297","title":"微泰医疗-B(02235)7月20日斥资约7.49万港元回购1.07万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2652502297","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652502297?lang=zh_cn&edition=full","pubTime":"2026-07-20 18:48","pubTimestamp":1784544492,"startTime":"0","endTime":"0","summary":"智通财经APP讯，微泰医疗-B(02235)发布公告，于2026年7月20日该公司斥资约7.49万港元回购1.07万股，回购价格为每股6.98至7.00港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1469873.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02235","BK1100"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120534085","title":"微泰医疗-B：7月17日回购1.78万股股份，耗资约12.57万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1120534085","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1120534085?lang=zh_cn&edition=full","pubTime":"2026-07-17 18:03","pubTimestamp":1784282582,"startTime":"0","endTime":"0","summary":"根据2026年7月17日发布的翌日披露报表，微泰医疗-B于香港联交所场内回购H股17,800股，占当日已发行股份总数的约0.0109%，每股回购价格介乎港币7.00元至7.10元，合计耗资约12.57万港元。本次回购完成后，公司已发行股份总数由163,210,942股降至163,193,142股，库藏股数量增至5,982,700股，合计已发行股本仍维持169,175,842股不变。本次回购后，公司剩余可回购股份数量为16,416,184股。公司表示，上述回购事宜已获董事会正式授权，并符合香港联合交易所有限公司证券上市规则及相关法规要求。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"微泰医疗-B：7月17日回购1.78万股股份，耗资约12.57万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02235"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652785473","title":"【券商聚焦】中信建投：建议关注Q2医疗设备高增长公司配置机会","url":"https://stock-news.laohu8.com/highlight/detail?id=2652785473","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652785473?lang=zh_cn&edition=full","pubTime":"2026-07-17 08:56","pubTimestamp":1784249774,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券研究指，板块26Q1业绩整体承压。医疗设备预计Q2招标偏弱，部分企业新品及海外驱动增长；医疗器械上游部分公司收入有望高增长；高值耗材受医疗合规要求提升影响，部分企业预计增长良好；IVD低基数下增速有望改善；家用器械部分企业有望延续高增长；医疗服务边际有所回暖。建议关注Q2高增长公司的配置机会，建议关注国产替代向中高端延伸，看好出海、新科技（AI、脑机接口）及并购整合等新技术落地。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250109/MWQ0NzJkZTcxMzM4ODY4MjA2MzM0OTUz.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MWQ0NzJkZTcxMzM4ODY4MjA2MzM0OTUz.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1986094","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","BK1587","BK1189","00853","HK0000165453.HKD","KCE","LU0173614495.USD","BK1574","01302","BK1617","BK1600","06826","BK1591","BK1247","601066","02235","BK1100","01066","BK1593","BK1142","BK1222","02252","BK1501","BK1502","BK1583","BK1610","LU0287142896.SGD","BK1571","BK1584","159873","BK1161","09996","02190","BK1615","BK1589","BK0276","BK1585","00241"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.0909},{"period":"1month","weight":-0.0286},{"period":"3month","weight":-0.0798},{"period":"6month","weight":-0.0945},{"period":"1year","weight":-0.1636},{"period":"ytd","weight":-0.1425}],"compareEarnings":[{"period":"1week","weight":0.0026},{"period":"1month","weight":-0.0102},{"period":"3month","weight":0.0276},{"period":"6month","weight":-0.0041},{"period":"1year","weight":0.0236},{"period":"ytd","weight":0.0008}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"微泰医疗器械（杭州）股份有限公司是一家主要从事医疗器械的研发、生产和销售的中国公司。该公司的主营业务是生产和销售血糖监测系统（BGMS）、持续葡萄糖监测系统（CGMS）和胰岛素泵系统。该公司在糖尿病监测、治疗、管理领域拥有产品组合，涵盖贴敷式胰岛素泵系统、持续葡萄糖监测系统、闭环人工胰腺系统、血糖监测系统以及糖尿病数字管理软件等产品。该公司在国内和国外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0,"avgChangeRate":-0.189861},{"month":2,"riseRate":0.4,"avgChangeRate":-0.078129},{"month":3,"riseRate":0.4,"avgChangeRate":0.009968},{"month":4,"riseRate":0.4,"avgChangeRate":-0.003701},{"month":5,"riseRate":0,"avgChangeRate":-0.088227},{"month":6,"riseRate":0.2,"avgChangeRate":-0.027697},{"month":7,"riseRate":0.2,"avgChangeRate":0.007766},{"month":8,"riseRate":0.6,"avgChangeRate":0.002033},{"month":9,"riseRate":0.2,"avgChangeRate":-0.031119},{"month":10,"riseRate":0.25,"avgChangeRate":-0.072372},{"month":11,"riseRate":0.8,"avgChangeRate":0.034888},{"month":12,"riseRate":0.8,"avgChangeRate":0.248824}],"exchange":"SEHK","name":"微泰医疗-B","nameEN":"MICROTECH MED-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"微泰医疗-B(02235)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供微泰医疗-B(02235)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"微泰医疗-B,02235,微泰医疗-B股票,微泰医疗-B股票老虎,微泰医疗-B股票老虎国际,微泰医疗-B行情,微泰医疗-B股票行情,微泰医疗-B股价,微泰医疗-B股市,微泰医疗-B股票价格,微泰医疗-B股票交易,微泰医疗-B股票购买,微泰医疗-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"微泰医疗-B(02235)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供微泰医疗-B(02235)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}